Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Knowing What Cidara Therapeutics is Doing for the Seasonal Flu

October 28, 2025 0

Cidara Therapeutics Cidara Therapeutics (CDTX) is using its proprietary Cloud break® platform to develop novel drug-Fc …

BridgeBio Pharma Reported Positive Phase 3 Results from FORTIFY the Phase 3 Pivotal Study of BBP-418 in People with Limb-Girdle Muscular Dystrophy Type 2I/R9

October 27, 2025 0

BridgeBio Pharma BridgeBio Pharma, Inc. is a new type of biopharmaceutical company founded to discover, create, …

The U.S. FDA Approved GSK Product Blenrepis for Treatment of Relapsed/Refractory Multiple Myeloma

October 24, 2025 0

GSK US FDA Approval Yesterday, October 23, 2025, GSK plc (GSK) announced the United States Food …

The FDA Approves Roche’s Gazyva/Gazyvaro for the Treatment of Lupus Nephritis

October 20, 2025 0

Roche in the NEWS Roche (RHHBY) announced Food and Drug Administration approval of Gazyva®/Gazyvaro®(obinutuzumab) for the …

U.S. FDA Approves Boehringer Ingelheim’s JASCAYD® (nerandomilast) Tablets as First New Treatment for Adults with Idiopathic Pulmonary Fibrosis

October 16, 2025 0

Boehringer Ingelheim USFDA Approval Boehringer Ingelheim JASCAYD® (nerandomilast) tablets are approved by the U.S. FDA as …

Why GRAL is Moving UP More Than Usual Today

October 16, 2025 0

Samsung and GRAIL Announce Strategic Collaboration to Bring GRAIL’s Galleri® Multi-Cancer Early Detection Test to Asia …

Regeneron: DB-OTO Results in Sustained Improvement in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss

October 14, 2025 0

The Great Story from Regerneron Pharmaceuticals Regeneron Pharmaceuticals (REGN) announced updated data for the Company’s investigational …

Akero Therapeutics Announced It Entered into a Definitive Agreement to be Acquired by Novo Nordisk

October 9, 2025 0

Akero Therapeutics Acquisition Agreement Today, October 9, 2025, Akero Therapeutics (AKRO) announced that it entered into …

U.S. FDA Lifts Clinical Hold on NUZ-001, Neurizon® Lead Investigational Therapy for ALS

October 6, 2025 0

Neurizon Therapeutics in the NEWS Today October 6, 2025, from Melbourne, Australia: Neurizon Therapeutics Limited (ASX: …

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

September 29, 2025 0

Genmab in the NEWS Denmark; UTRECHT, The Netherlands; Today, Genmab (GMAB) and Merus (MRUS) announced that …

uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease

September 25, 2025 0

uniQure in the NEWS On September 24, 2025, uniQure N.V. (QURE) - a gene therapy company advancing transformative …

Important: Two Press Releases in the Past 2 Days from Grail & Intellia Therapeutics

September 24, 2025 0

Important News from Grail Inc. and Intellia Therapeutics Grail Inc Press Realease GRAL to Present New …

VectorY Therapeutics and Shape Therapeutics, both private firms Announce Option and License Agreement to Advance Vectorized Antibodies for the treament of Neurodegenerative Diseases Using an AAV5-Derived CNS Capsid

September 18, 2025 0

VectorY Therapeutics in the NEWS September 18, 2025 – VectorY Therapeutics, a biotechnology company developing innovative …

In Data Presented at the European Association for the Study of Diabetes and NEUROdiabetis Meetings, Lexicon Pharmaceuticals Product Pilavapadin Provided Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain.

September 18, 2025 0

Lexicon Pharmaceuticals in the NEWS Yesterday, September 17, 2025, Lexicon Pharmaceuticals (LXRX) announced the presentation of …

Eli Lilly’s Oral GLP-1, Orforglipron, is Superior to Oral Semaglutide in Head-to-Head Trial

September 17, 2025 0

Eli Lilly Eli Lilly and Company (LLY) today September 17, announced positive topline results from ACHIEVE-3, Phase …

Jazz Pharmaceuticals to Treat H3 K27M-Mutant Diffuse Midline Glioma

September 16, 2025 0

Jazz Pharmaceuticals On September 9, 2025, Jazz Pharmaceuticals plc (JAZZ) announced that Modeyso™ (dordaviprone) is recommended by …

The FDA is Taking Concrete Steps to Reduce Opioid Misuse, Addiction and Overdose Strengthening Guidance on Their Appropriate Use

September 11, 2025 0

Xenon Pharmaceuticals A Company Treating Chronic Pain Xenon Pharmaceuticals (XENE) - a neuroscience-focused biopharmaceutical company dedicated …

Alnylam Pharmaceuticals Announces Proposed Offering of $500 Million Convertible Senior Notes. The Stock’s Price is Soaring.

September 9, 2025 0

Alnylam Pharmaceuticals Press Release Alnylam Pharmaceuticals, Inc. (ALNY), the leading RNAi therapeutics company, announced today that …

Regeneron Pharmaceuticals Libtayo® Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-Small Cell Lung Cancer

September 9, 2025 0

Regeneron Pharmaceuticals Announcement Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a …

Alkermes: Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025

September 8, 2025 0

Alkermes in the NEWS Today, Alkermes Inc., (ALKS) announced detailed positive results from the Vibrance-1 phase …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd

Knowing What Cidara Therapeutics is Doing for the Seasonal Flu

BridgeBio Pharma Reported Positive Phase 3 Results from FORTIFY the Phase 3 Pivotal Study of BBP-418 in People with Limb-Girdle Muscular Dystrophy Type 2I/R9

The U.S. FDA Approved GSK Product Blenrepis for Treatment of Relapsed/Refractory Multiple Myeloma

The FDA Approves Roche’s Gazyva/Gazyvaro for the Treatment of Lupus Nephritis

U.S. FDA Approves Boehringer Ingelheim’s JASCAYD® (nerandomilast) Tablets as First New Treatment for Adults with Idiopathic Pulmonary Fibrosis

Why GRAL is Moving UP More Than Usual Today

Regeneron: DB-OTO Results in Sustained Improvement in Hearing and Speech Perception in Children with Profound Genetic Hearing Loss

Akero Therapeutics Announced It Entered into a Definitive Agreement to be Acquired by Novo Nordisk

U.S. FDA Lifts Clinical Hold on NUZ-001, Neurizon® Lead Investigational Therapy for ALS

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease

Important: Two Press Releases in the Past 2 Days from Grail & Intellia Therapeutics

VectorY Therapeutics and Shape Therapeutics, both private firms Announce Option and License Agreement to Advance Vectorized Antibodies for the treament of Neurodegenerative Diseases Using an AAV5-Derived CNS Capsid

In Data Presented at the European Association for the Study of Diabetes and NEUROdiabetis Meetings, Lexicon Pharmaceuticals Product Pilavapadin Provided Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain.

Eli Lilly’s Oral GLP-1, Orforglipron, is Superior to Oral Semaglutide in Head-to-Head Trial

Jazz Pharmaceuticals to Treat H3 K27M-Mutant Diffuse Midline Glioma

The FDA is Taking Concrete Steps to Reduce Opioid Misuse, Addiction and Overdose Strengthening Guidance on Their Appropriate Use

Alnylam Pharmaceuticals Announces Proposed Offering of $500 Million Convertible Senior Notes. The Stock’s Price is Soaring.

Regeneron Pharmaceuticals Libtayo® Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-Small Cell Lung Cancer

Alkermes: Detailed Positive Results from Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at World Sleep Congress 2025